"President Had Stakes In Makers Of Antibody Cocktail, Remdesivir"—Will This Be The Next Conspiracy Theory?
Print Friendly and PDF

That Trump didn’t really have COVID, he just faked it to promote his golf buddy’s stock? From USA Today:

Trump COVID-19 treatment: President had stakes in Regeneron and Gilead, makers of antibody cocktail, Remdesivir

Kelly Tyko, USA TODAY

President Donald Trump previously reported he earned capital gains from Regeneron Pharmaceuticals and Gilead Sciences Inc., the manufacturers of two of the medicines he’s taken as part of his COVID-19 treatment plan.

According to a 2017 financial disclosure form filed with the U.S. Office of Government Ethics in June 2017, Trump had a capital gain of $50,001 to $100,000 for Regeneron Pharmaceuticals and $100,001 to $1 million for Gilead Sciences Inc. The form notes the information was of April 15, 2017.

Trump’s subsequent disclosure forms, including his 2020 form signed July 31, did not list Regeneron or Gilead.

Trump received a single 8-gram dose of Regeneron’s polyclonal antibody cocktail as a precautionary measure, according to his physician Sean Conley. The antibody cocktail is in four late-stage clinical trials, and its safety and efficacy have not been fully evaluated by any regulatory authority, the company said on its webpage.

As part of Operation Warp Speed, New York state-based Regeneron won a $450 million federal contract in July to manufacture and supply the company’s antibody cocktail REGN-COV2.

It’s so new that it doesn’t appear to have a name yet. But the logic behind it makes a lot of sense, and the very early clinical trials look like it’s the best treatment yet.

The New York Times reported Friday that Regeneron’s chief executive, Dr. Leonard S. Schleifer, a member of Trump’s golf club in Westchester County, New York, said Trump’s medical staff reached out to the company for permission to use the drug and the Food and Drug Administration cleared it. …

“When it’s the president of the United States, of course, that gets – obviously – gets our attention,” Schleifer told the Times. Regeneron stock rose $19.20 a share in after-hours trading.

Seriously, this stuff sounds pretty good.

[Comment at Unz.com]

Print Friendly and PDF